Archive | Canna~Fangled Abstracts RSS feed for this section



From “Azalla” to Anandamide: Distilling the Therapeutic Potential of Cannabinoids

Rajiv RadhakrishnanCorrespondence information about the author Rajiv RadhakrishnanEmail the author Rajiv Radhakrishnan , David A. Ross Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut PlumX Metrics DOI:  Abstract > Full Text > Images >References Article Outline Acknowledgments and Disclosures References Root of caper which is on a grave, root of acacia…[and] azalla (cannabis); these seven drugs […]

The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Clin Auton Res. 2017 Dec 8. doi: 10.1007/s10286-017-0488-5. [Epub ahead of print] Sierra S1,2, Luquin N3, Navarro-Otano J4. Author information Abstract RATIONALE: Cardiovascular disease is now recognized as the number one cause of death in the world, and the size of the population at risk continues to increase rapidly. The dysregulation of the endocannabinoid (eCB) […]

Could cannabis liberalisation lead to wider changes in drug policies and outcomes?

Int J Drug Policy. 2017 Dec 8. pii: S0955-3959(17)30324-9. doi: 10.1016/j.drugpo.2017.10.004. [Epub ahead of print] Hughes B1, Wiessing L2, Des Jarlais D3, Griffiths P4. Author information Abstract Cannabis policies are changing in some countries. This may have consequences that extend beyond cannabis-specific outcomes, such as an impact on the consumption patterns of other substances. Changes […]

Associations between medical cannabis and other drug use among unstably housed women.

Int J Drug Policy. 2017 Dec 8;52:45-51. doi: 10.1016/j.drugpo.2017.11.009. [Epub ahead of print] Meacham MC1, Ramo DE2, Kral AH3, Riley ED4. Author information Abstract BACKGROUND: Several studies suggest that U.S. state-level legalization of cannabis for medical purposes may be associated with reductions in opioid use; yet its relationship with stimulant use, particularly in high-risk populations […]

Medical marijuana laws and adolescent use of marijuana and other substances: Alcohol, cigarettes, prescription drugs, and other illicit drugs.

Drug Alcohol Depend. 2017 Dec 7;183:62-68. doi: 10.1016/j.drugalcdep.2017.10.021. [Epub ahead of print] Cerdá M1, Sarvet AL2, Wall M3, Feng T4, Keyes KM5, Galea S6, Hasin DS7. Author information Highlights •Substance use decreased among 8th graders after medical marijuana use was legalized. •Substance use did not change among 10th graders following legalization. •Prescription drug and cigarette […]

Differential neuromodulatory role of endocannabinoids in the rodent trigeminal sensory ganglion and cerebral cortex relevant to pain processing.

Neuropharmacology. 2017 Dec 7. pii: S0028-3908(17)30602-0. doi: 10.1016/j.neuropharm.2017.12.013. [Epub ahead of print] Eroli F1, Loonen ICM2, van den Maagdenberg AMJM3, Tolner EA4, Nistri A5. Author information Abstract Endocannabinoids are suggested to control pain, even though their clinical use is not fully validated and the underlying mechanisms are incompletely understood. To clarify the targets of endocannabinoid […]

Endogenous dopamine and endocannabinoid signaling mediate cocaine-induced reversal of AMPAR synaptic potentiation in the nucleus accumbens shell.

Neuropharmacology. 2017 Dec 7. pii: S0028-3908(17)30600-7. doi: 10.1016/j.neuropharm.2017.12.011. [Epub ahead of print] Ingebretson AE1, Hearing MC2, Huffington ED1, Thomas MJ3. Author information Abstract Repeated exposure to drugs of abuse alters the structure and function of neural circuits mediating reward, generating maladaptive plasticity in circuits critical for motivated behavior. Within meso-corticolimbic dopamine circuitry, repeated exposure to […]

Cannabinoids for epilepsy: What do we know and where do we go?

Epilepsia. 2017 Dec 6. doi: 10.1111/epi.13973. [Epub ahead of print] Brodie MJ1, Ben-Menachem E2. Author information Abstract Over the past decade there has been an increasing interest in using cannabinoids to treat a range of epilepsy syndromes following reports of some remarkable responses in individual patients. The situation is complicated by the fact that these […]

Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells.

United European Gastroenterol J. 2017 Dec;5(8):1108-1115. doi: 10.1177/2050640617698622. Epub 2017 Mar 13. Gigli S1, Seguella L1, Pesce M2, Bruzzese E3, D’Alessandro A2, Cuomo R2, Steardo L1, Sarnelli G2, Esposito G1. Author information Abstract BACKGROUND: Clostridium difficile toxin A is responsible for colonic damage observed in infected patients. Drugs able to restore Clostridium difficile toxin A-induced […]

LH-21 and Abn-CBD improve β-cell function in isolated human and mouse islets through GPR55-dependent and -independent signalling.

Diabetes Obes Metab. 2017 Dec 5. doi: 10.1111/dom.13180. [Epub ahead of print] Ruz-Maldonado I1, Pingitore A1, Liu B1, Atanes P1, Huang GC1, Baker D2, Alonso FJ3, Bermúdez-Silva FJ4,5, Persaud SJ1. Author information Abstract AIMS: CB1 and GPR55 are GPCRs expressed by islet β-cells. Pharmacological compounds have been used to investigate their function, but off-target effects […]